By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Kolltan Pharmaceuticals Inc. 

300 George Street
Suite 530
New Haven  Connecticut  06511  U.S.A.
Phone: 203-773-3000 Fax: 203-773-1300


SEARCH JOBS

Kolltan, a privately held clinical-stage company, is focused on advancing a new generation of therapeutics in oncology and other diseases by discovering and developing novel biologic agents designed to modulate the function of receptor tyrosine kinases (RTKs). Kolltan is led by an experienced team of executives and scientists with a deep understanding of RTKs, their ligands, and cellular signaling. Located adjacent to the Yale Medical School in New Haven, Connecticut, Kolltan is working in close collaboration with the laboratory of Kolltan co-founder, Dr. Joseph Schlessinger, as well as the Yale medical and scientific community to bring important medicines to cancer patients and other patients with serious diseases. The Company's R&D pipeline is advancing rapidly, with the first clinical trial initiated in January 2014.


Key Statistics


Email: info@kolltan.com
Ownership: Private

Web Site: Kolltan Pharmaceuticals Inc.
Employees:
Symbol: 
 









Company News
Kolltan Pharmaceuticals Inc. To Present KTN0158 Preclinical Data At The European Cancer Congress 2015 7/22/2015 8:59:04 AM
ASCO15: Kolltan Pharmaceuticals Inc. Announces Presentation Of KTN3379 Interim Phase 1b Data At 2015 American Society Of Clinical Oncology Annual Meeting 6/1/2015 2:11:21 PM
Kolltan Pharmaceuticals Inc.Dr. Joseph Schlessinger Named To Medicine Maker Power List 2015 5/15/2015 12:09:53 PM
Kolltan Pharmaceuticals Inc. To Present At The 11th Annual PEGS - The Essential Protein Engineering Summit 4/29/2015 12:29:11 PM
Kolltan Pharmaceuticals Inc. Appoints Industry Veteran Frank Karbe To Its Board Of Directors 4/13/2015 10:35:55 AM
Kolltan Pharmaceuticals Inc. To Present At The 2015 American Association for Cancer Research Annual Meeting 3/20/2015 9:32:22 AM
Kolltan Pharmaceuticals Inc. To Present At The 22nd Annual Future Leaders In The Biotech Industry Conference 3/13/2015 10:12:09 AM
Cancer Biotech Kolltan Pharmaceuticals Inc. Withdraws $86 Million IPO 1/29/2015 6:13:06 AM
Kolltan Pharmaceuticals Inc. Presents KTN3379 Clinical And Preclinical Data At International Cancer Meeting 11/20/2014 11:11:07 AM
Kolltan Pharmaceuticals Inc. Begins Phase 1b Cancer Study Evaluating KTN3379 In Combination With Multiple Targeted Therapies At Sarah Cannon Research Institute 11/3/2014 10:41:58 AM
123
//-->